West Pharma (WST) Tops Q4 EPS by 13c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q4 EPS of $2.04, $0.13 better than the analyst estimate of $1.91. Revenue for the quarter came in at $730.8 million versus the consensus estimate of $710.2 million.
GUIDANCE:
West Pharma sees FY2022 EPS of $9.20-$9.35, versus the consensus of $9.06. West Pharma sees FY2022 revenue of $3.05-3.075 billion, versus the consensus of $3.07 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Oxford Square Capital Corp. (OXSQ) Misses Q3 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
